Use of Pharmacogenetic Testing in Routine Clinical Practice Improves Outcomes for Psychiatry Patients

Timothy Ramsey1,2, Elizabeth Griffin3, Qian Liu4, Mark D Brennan1 and Sandeep Vaishnavi2,3

1SureGene, LLC 600 Envoy Circle Louisville, Kentucky, USA
2Clinical Reference Laboratory, Lenexa, Kansas, USA
3The Neuropsychiatric Clinic [NPC] at Carolina Partners, North Carolina, USA
4HTG Molecular Inc, Tucson, Arizona, USA
5Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina, USA

Abstract

Introduction: In clinical trials, pharmacogenetic testing has been shown to improve outcomes in psychiatric patients. It is unclear if these improved outcomes translate into routine clinical practice. A significant impediment to evaluation of pharmacogenomics testing in routine practice has been a lack of quantifiable outcomes data. This study leverages longitudinal symptom evaluations using validated computer-based assessments to evaluate the impact of pharmacogenetic testing across a number of psychiatric symptom dimensions in routine clinical practice.

Methods: This study retrospectively evaluated data from The Neuropsychiatric Clinic, Carolina Partners, Raleigh, NC who were either tested (n=74) or untested (n=57) with a commercial genetic test at physician’s discretion. All subjects had at least four evaluations with the NeuroPsych Questionnaire-Short Form. Treatment effects were estimated using a general linear model incorporating all time points and baseline values for the 12 NPQ individual items.

Results: Tested patients experienced significantly greater improvement over time in a number of symptom dimensions. Aggression, anxiety, depression, fatigue, impulsivity, mood instability, panic, and suicide symptoms improved more in tested patients compared to untested patients (p=10^-4 to 10^-20).

Conclusions: In routine clinical practice, pharmacogenetic testing can enable significant improvement in clinically outcomes for psychiatric patients with a variety of diagnoses.

Keywords: SureGene test; NeuroPsych Questionnaire; Computer-based assessment; Translational medicine; Psychiatric pharmacogenetics; SUIT4A1

Introduction

Despite a substantial number of FDA-approved medications, many psychiatric conditions remain challenging to treat. In particular, depression and psychosis have low success rates with the initially selected medication. In fact, the initial medication typically achieves meaningful response in 40% or less of patients [1].

The advent of personalized medicine offers an objective, biological tool to enhance success rates. Genetic variation in metabolic enzyme genes has long been known to alter the pharmacokinetics of drug metabolism. Indeed, many psychiatric medications have language in their labels specifically highlighting metabolism by enzymes with known genetic variants that alter activity.

Retrospective analysis of clinical cohorts demonstrates the correlation of genetic information with various outcomes De Leon et al. have described how cytochrome p450 (CYP) 2D6 poor metabolizer status greatly increases the risk of adverse events for risperidone-treated patients [2-8]. The Mayo clinic has an extensive publication history dealing with pharmacogenetic (PGx) testing and depression [3,4]. A number of groups have reported on the impact of genetic variation in the serotonin transporter [5,6]. The Clinical Antipsychotic Trials of Intervention Effectiveness working group has published the results of PGx analysis of response to antipsychotics [7,8]. Similarly, many analyses for large multicenter trials looking at the impact of genetics on treatment response in depression have been published, including both gene-specific and large scale genetic analyses [9-12].

Within the past few years, some prospective studies have been conducted. The Mayo group has published several studies showing that therapy directed by genetic testing outperforms standard of care for the treatment of depression [3]. Herbold et al. reported on a prospectively designed study demonstrating that PGx-guided therapy led to lower health care costs, presumably through better treatment outcomes in schizophrenia [13]. The two studies shared a focus on CYP variants. The Mayo studies also evaluated variation in the gene encoding the serotonin transporter. Each of these studies demonstrated the benefits of incorporating PGx testing in a controlled setting. Recently, consortia have begun publishing consensus recommendations for antidepressant dosing based on metabolism gene status [14]. Oligiati et al. reported that PGx testing can be cost effective in high income European Union countries, which have economies similar to the United States [15]. More recently, confirmatory findings are beginning to emerge from studies in naturalistic settings [5].

Results in a controlled, structured environment in the context of clinical trials may not predict outcomes in real-world environments. Additionally, controlled studies often do not reflect racial or financial
diversity. Accordingly, it has becoming increasingly important to assess the efficacy of medical interventions in routine clinical practice. These kinds of assessments can be helpful to understand if technological advances (such as PGx testing) improve quality of care, and consequently, if they are cost-effective.

The present study examined the impact of use of a commercial PGx test, the SureGene Test for Antipsychotic and Antidepressant Response (STA2R), in routine clinical practice in a private setting (The Neuropsychiatric Clinic [NPC] at Carolina Partners in Raleigh, North Carolina). The NPC patient population demographics are reflective of the American South-East modified by the presence of numerous Universities and high technology companies located in the Research Triangle Area of North Carolina. Typically, evaluating results in a non-controlled setting can be troublesome due to lack of standardized measures of efficacy. However, the NPC routinely assesses patients with validated computer-based self-report mechanisms, the Neuropsych Questionnaire – Short Form (NPQ) [16]. The NPQ is part of a commercially available computerized neurocognitive test battery (CNS Vital Signs). The NPQ has been shown to correlate with standardized rating scales including the Hamilton and Beck depression and anxiety rating scales [16]. This availability of a consistent measure of psychiatric symptom burden enabled a direct comparison between tested and untested patients and evaluation of the benefit of STA2R testing in a routine setting.

Patients and Methods

Patients

The patients for this analysis came from The NPC at Carolina Partners, a private practice in Raleigh, North Carolina. The Neuropsychiatric Clinic staff routinely assesses patients with various computer-based assessments (CBAs). These assessments are monitored by psychometricians. In particular, most patients complete the NeuroPsych Questionnaire – Short Form (NPQ) at each visit [16].

The inclusion and exclusion criteria for the study were as follows:

1. All patients with at least four assessments with NPQ between July 2012 and August 2013 were included.

2. Patients that had undergone transcranial magnetic stimulation (TMS) therapy at the NPC at any time were excluded.

Both tested and untested patients that met these criteria were included in this retrospective analysis. There were sufficient NPQ data for a total of 57 untested and 74 tested individuals to be included in the study. Table 1 lists the frequency of the various diagnoses for tested and untested subjects. Most subjects had more than one diagnosis. As expected for a Neuropsychiatric practice, the majority of patients also had at least one neurological disorder.

Clinical data

The primary assessment used to determine clinical progress for this study was the NPQ. This self-reported CBA demonstrates good reliability both for retesting patients over time and between raters, and it is sensitive to treatment effects [16]. The test is provided through an online questionnaire, and its ease of use along with the psychometric properties noted above allows it to be used routinely in clinical practice. Only retrospective, de-identified clinical outcomes data were used. The principles outlined in the Declaration of Helsinki were followed.

Statistical methods

We used the Student's t-test to test the hypothesis that there were no significant differences between baseline NPQ scores of tested and untested patients. To test whether the genetic testing influenced patients' improvement as measured by the change of NPQ item score (dScore), we built a general linear model for dScore that included days from the initial assessment and median centered baseline, both nested in Case (tested) / Control (untested) status. We used all available observations up to day 300 from each subject to fit the model [17]. We used the model for two purposes. First, the model tested the hypothesis that the slope of the line indicating change over time differed significantly from zero (i.e., a significant difference indicates that there is a treatment effect). Second, the model was used to predict response at 300 days of treatment at the NPC. We then compared the average predicted improvement at 300 days for tested versus untested patients using the t-test and further evaluated those dimensions that showed significant differences using linear regression with covariate adjustment for baseline score.

Genetic testing

The patients were tested with the commercially available STA2R test. This test includes several genetic markers that provide information regarding the likely efficacy of olanzapine (sulfotransferase family member 4A1 gene [SULT4A1]) [9,10], and of selective serotonin reuptake inhibitors (serotonin transporter gene [SLC6A4]) [18,19]. Additionally, STA2R provides information on the probable, genetically determined activity level of numerous cytochrome P450 genes (CYP) 1A2, 2C9, 2C19, 2D6, and 3A4/5. The CYP enzymes metabolize a broad range of medications including, but not limited to, commonly used antipsychotics (aripiprazole, clozapine, haloperidol, olanzapine, quetiapine, and risperidone) and antidepressants (amitriptyline, citalopram, duloxetine, escitalopram, fluoxetine, nortriptyline, and venlafaxine). For patients having CYP genetic variation that results in altered activity levels, STA2R provides information that facilitates physician-directed dose adjustments for many of the most commonly prescribed medications.

Results

A total of 131 patients, 74 tested and 57 untested, from the NPC met the study criteria. For the tested patients, Table 2 lists the tested genes, commonly used drugs impacted by the tested gene, and the frequency of test results for each gene indicating altered metabolism, function, or efficacy in the tested population. All of the genes had a meaningful percentage of patients with altered function, ranging from 8% for CYP 3A4 to 86% for CYP 1A2. Predictors of efficacy, SULT4A1 and SLC6A4 (for olanzapine and SSRIs respectively), occurred frequently, 29% and 76% respectively. Of tested patients, only 1 of 74 had no impactful variants.

Table 3 lists the mean scores for each of the 12 NPQ items at baseline. For eight of the 12 items, the tested group had higher average scores, indicating a higher symptom burden.

| Diagnosis          | Tested | Untested |
|--------------------|--------|----------|
| ADHD               | 0.13   | 0.25     |
| Anxiety Disorder   | 0.45   | 0.37     |
| Bipolar Disorder   | 0.16   | 0.11     |
| Depressive Disorder| 0.54   | 0.33     |
| Neurological*      | 0.59   | 0.65     |

*Most patients had multiple diagnoses. Therefore, the sum of the frequencies exceeds one. *Neurological includes several different diseases, disorders, and injuries such as autism, epilepsy, migraine, mild cognitive impairment, Parkinson's, and traumatic brain injury.

Table 1: Frequency of various diagnoses in the study.
Using the statistical model described in the Methods section, we evaluated whether or not the slope of the line describing patient improvements over time differed significantly from zero. The model used for this analysis included an adjustment for baseline (median-centered). For all symptom dimensions, baseline score was a highly significant term in the model, with all p-values < 10^-6. Table 4 lists the improvement over time that differed significantly from zero. The model we evaluated whether or not the slope of the line describing patient decreases in symptom burden than untested subjects.

Table 2 provides the mean model-predicted response for each of the symptom dimensions for tested and untested patients. As above, the model corrects for differences in baseline scores. Notably, for eight of the 12 dimensions, tested patients experienced significantly greater decreases in symptom burden than untested subjects.

While the predictive model incorporated baseline scores, we performed a linear regression analysis that explicitly included a baseline covariate to eliminate the possibility that the significant differences between tested and untested patients could be attributed to the significant differences in baseline values reported in Table 3. Table 6 shows the results from a linear regression analysis of the significant items from Table 5: aggression, anxiety, depression, fatigue, impulsivity, mood instability, panic, and suicide. After correction for baseline score, all eight symptom dimension demonstrated significantly greater symptom reduction in tested subjects. Indeed, all dimensions except depression retained or improved the degree of significance. We also calculated the effect size for the difference in response between tested and untested patients. All eight dimension had an effect size (0.25) greater that often used to separate a drug from placebo in clinical trials.

Discussion: We found that multiple, clinically important psychiatric symptoms improved significantly more for patients with pharmacogenetic (PGx) testing compared to those that were not tested. On average, the tested patients tended to have higher baseline NPQ values than untested patients, reflecting a likely bias toward performing PGx testing for patients who are more ill and/or treatment refractory. It is important to note that our response model incorporated baseline NPQ values, and, therefore, the greater improvement seen for tested patients cannot be

### Table 2: Genes tested, frequency of variants with clinical implications, and drugs impacted.

| Gene Tested | Clinical Utility of Test |
|-------------|--------------------------|
| SULT4A1     | 29% of subjects had a SULT4A1 genotype that exhibits superior average response to olanzapine and may have less susceptibility to olanzapine induced-weight gain. |
| SLC6A4      | 26% of subjects had a genotype that indicated likely lower production of the serotonin transporter and expected to have “poor” response to SSRIIs; 50% had intermediate levels of SLC6A4. |
| CYP2D6      | 42.6% of subjects had altered CYP2D6 metabolism. The test report provided information supporting avoiding or adjusting the dose of numerous psychotropic drugs, including aripiprazole, haloperidol, risperidone, duloxetine, fluoxetine, paroxetine, venlafaxine, many tricyclic antidepressants, amphetamine, atomoxetine, corderine, hydrocodone, and tramadol. |
| CYP2C9      | 33.3% of subjects had altered CYP2C9 metabolism. The test report provided information supporting avoiding or adjusting the dose of numerous drugs including NSAIDS and Sulfonylureas. |
| CYP2C19     | 65.3% of subjects had altered CYP2C19 metabolism. The test report provided information supporting avoiding or adjusting the dose of numerous psychotropic drugs, including amitriptyline, citalopram, desimipramine, imipramine, sertraline, and diazepam. |
| CYP1A2      | 86.4% of subjects had enhanced induction of CYP1A2, especially in smokers. The test report provided information supporting adjusting the dose of numerous psychotropic drugs, including bupropion, clozapine, duloxetine, and olanzapine. |
| CYP3A4/5    | 6.8% of subjects had decreased CYP3A4/5 metabolism. The test report provided information supporting avoiding or adjusting the dose of numerous psychotropic drugs, including carbamazepine, desvenlafaxine, fentanyl, lurasidone, nortriptyline, quetiapine, trazodone, vilazodone, and ziprasidone. |

### Table 3: Baseline values for the twelve symptom dimensions captured by the NPQ.

| Dimension | Tested Mean | Untested Mean | Difference | p-value
|-----------|------------|---------------|------------|-------|
| Aggression | 49.6       | 26.9          | 22.72      | 0.02  |
| Anxiety   | 128.2      | 93.8          | 34.38      | 0.01  |
| Attention | 147.6      | 140.4         | 7.22       | 0.67  |
| Depression| 137.9      | 85.6          | 52.38      | 0.0001|
| Fatigue   | 158.7      | 101.3         | 57.45      | 0.001 |
| Impulsive | 87.2       | 80.4          | 6.87       | 0.57  |
| Memory    | 139.7      | 135.2         | 4.47       | 0.80  |
| Mood instability | 127.6 | 92.6          | 34.99      | 0.03  |
| Pain      | 113.4      | 83.8          | 29.57      | 0.07  |
| Panic     | 66.7       | 32.1          | 34.62      | 0.02  |
| Sleep     | 135.3      | 82.2          | 53.12      | 0.006 |
| Suicide   | 28.2       | 10.4          | 17.71      | 0.02  |

1NPQ symptom domain; 2Mean value of NPQ values at baseline, i.e. first rating for the “Untested” group and last test prior to being tested for the “Tested” group; 3Mean tested minus mean untested score; 4T-test for difference between the means; 5Mean tested minus mean untested score; 6Mean tested minus mean untested score; 7T-test for difference between the means; 8Mean tested minus mean untested score.
| Dimension | Tested | Tested | p-value | Untested | Untested | p-value |
|-----------|--------|--------|---------|----------|----------|---------|
| Aggression | -0.11  | 0.02²  |        | -0.04  | 0.29     |
| Anxiety²  | -0.26  | 0.0006³|         | -0.05  | 0.43     |
| Attention  | -0.07  | 0.41   |         | -0.06  | 0.32     |
| Depression | -0.18  | 0.02²  |         | -0.05  | 0.41     |
| Fatigue    | -0.17  | 0.05²  |         | -0.06  | 0.35     |
| Impulsive  | -0.13  | 0.05²  |         | -0.06  | 0.23     |
| Memory     | -0.07  | 0.35   |         | -0.08  | 0.18     |
| Mood Instability | -0.22 | 0.006³|         | -0.13  | 0.04⁴    |
| Pain       | 0.04   | 0.56   |         | 0.01   | 0.79     |
| Panic³    | -0.24  | 0.001¹|         | 0.04   | 0.48     |
| Sleep      | 0.05   | 0.64   |         | 0.07   | 0.38     |
| Suicide    | -0.06  | 0.16   |         | 0.01   | 0.62     |

¹The estimate is the amount the patient improved (negative numbers) or worsened (positive numbers) for each day of treatment. The model duration of treatment is 300 days. Therefore, a dimension with an estimate of -0.1 improved 30 points on that symptom dimension, and an estimate of -0.25 equals a 75 point decrease in that measure; ²The p-value tests if the slope is significantly different from zero; ³Tested patients performed significantly better than untested (p≤0.05); ⁴p-values had suggestive significance (p<0.2) after correction for multiple comparisons; ⁵p-values remained significant (p<0.05) after correction for multiple comparisons.

Table 4: Estimated daily change in NPQ scores in Tested and Untested patients derived evaluated with a general linear model incorporating data from all observations, baseline symptom scores, and tested status.

| Dimension | Tested | Tested | SD¹ | Beta² | p-value³ | Effect size⁴ |
|-----------|--------|--------|-----|-------|----------|--------------|
| Aggression | -39.1  | 32.0   | -10.1 | 20.4  | -29.0   | 6.5x10⁻⁸   |
| Anxiety    | -71.5  | 26.2   | -14.7 | 27.3  | -56.8   | 8.3x10⁻²² |
| Attention  | -28.8  | 37.5   | -31.5 | 36.5  | 2.7    | 7.1x10⁻¹   |
| Depression | -60.3  | 36.5   | -19.5 | 34.7  | -40.9   | 8.2x10⁻¹² |
| Fatigue    | -59.3  | 43.6   | -9.9  | 37.4  | -49.5   | 7.7x10⁻¹² |
| Impulsive  | -35.1  | 20.7   | -13.9 | 21.5  | -21.2   | 7.8x10⁻¹   |
| Memory     | -27.9  | 36.0   | -30.2 | 34.9  | 2.3    | 7.3x10⁻¹   |
| Mood Instability | -70.1 | 34.1   | -32.5 | 31.6  | -37.5   | 3.2x10⁻⁸   |
| Pain       | 3.4    | 33.3   | -8.1  | 29.8  | 11.5    | 6.2x10⁻²   |
| Panic      | -48.6  | 26.2   | 13.1  | 28.9  | -61.7   | 8.8x10⁻²¹ |
| Sleep      | -9.4   | 66.1   | 5.8   | 46.4  | -15.2   | 1.7x10⁻¹   |
| Suicide    | -23.8  | 35.2   | 2.0   | 13.4  | -25.8   | 4.9x10⁻⁸   |

¹Each row represents one of the twelve symptom dimensions for which the NPQ provides quantitative values of severity; ²Mean is the mean of the model predicted values for each of the two patient groups; ³SD is the standard deviation of the mean; ⁴The difference is calculated as (Mean of Tested) – (Mean of Untested). A negative number indicates that Tested patients experienced greater symptom reduction than Untested patients; ⁵p-value is calculated by applying t-test to the distribution of the change in dScore for each symptom dimension for Tested vs. Untested patients.

Table 5: Comparison of predicted change in NPQ values of Tested versus Untested subjects using the general linear model to predict change the change at day 300.

| Dimension | SD¹ | Beta² | p-value³ | Effect size⁴ |
|-----------|-----|-------|----------|--------------|
| Aggression | 30.9 | -18.4 | 1.1x10⁻¹² | -0.59       |
| Anxiety    | 38.2 | -41.6 | 8.7x10⁻¹⁰ | -1.06       |
| Depression | 41.3 | -16.3 | 1.2x10⁻⁹  | -0.39       |
| Fatigue    | 47.0 | -24.8 | 4.1x10⁻¹² | -0.53       |
| Impulsive  | 23.8 | -16.4 | 6.4x10⁻¹⁸ | -0.69       |
| Mood Instability | 38.3 | -23.7 | 8.5x10⁻¹⁴ | -0.62       |
| Panic      | 41.7 | -46.5 | 8.8x10⁻²¹ | -1.12       |
| Suicide    | 29.9 | -12.9 | 4.9x10⁻⁸  | -0.43       |

¹Each row represents one of the twelve symptom dimensions for which the NPQ provides quantitative values of severity; ²SD is the standard deviation of the model predicted values; ³Beta is the regression coefficient for tested status, i.e. the difference change attributable to tested status (negative values indicate greater response in tested compared to untested patients); ⁴p-value represents the significance of the value of the tested variable, i.e. p-values less than 0.05 indicate that tested status is a significant contributor to response; ⁵Effect size is a measure of the relative magnitude of the response and is calculated by Beta/SD

Table 6: Linear regression analysis of predicted change in NPQ values at day 300 using baseline NPQ score as a covariate.

attributed to higher baseline values. The magnitude of the enhanced response enabled the tested patients to achieve similar final symptom burdens despite having significantly higher baseline values for many dimensions. Furthermore, to rule out the possibility that the observed
difference was driven by differences in baseline score, we conducted linear regression analysis including baseline score as covariate, which confirmed that a significant portion of the observed difference was due to tested status.

For three of the four dimensions that did not show superior improvement in tested versus untested patients (memory, pain, and sleep), the test results did not provide information that would meaningfully impact the treatment decision. For attention, the test results provided information regarding dosing of amphetamines, patients for whom atomoxetine was inappropriate, and no information regarding use of methylphenidate. Conversely, with the exception of fatigue, all of the dimensions for which tested subjects displayed superior response compared to untested patients were treated extensively with antidepressants and antipsychotics. As shown in Table 6, most test results will have vital information concerning the selection and/or dosing of the commonly used antidepressants and antipsychotics. For example, seventy to ninety percent of test reports will provide actionable information on the most common SSRIs. Similarly, over fifty percent of test reports will provide actionable information regarding the use and/or dosing of aripiprazole, olanzapine, risperidone, and/or quetiapine.

While this study had several differences from tightly controlled clinical trials, such as baseline differences between the two study groups, lack of randomization and blinding, as well as inclusion of multiple diagnoses, these issues are an intrinsic component of routine clinical practice [3,4,20-24]. Additionally, rather than focusing on a single, disease specific efficacy measure, e.g. Hamilton Rating Scale for Depression or Positive and Negative Syndrome Scale, this study focused on improvement across a wide range of common psychiatric symptoms that are more reflective of typical psychiatric patient populations. Furthermore, this study did not dictate a specific treatment algorithm or plan. The study simply provided the treating physician with information regarding how the biology and genetics of individual patients was likely to influence the pharmacokinetics and pharmacodynamics of commonly used psychotropic medications and classes of medication. The treating physician then incorporated this information into his personalized treatment plan for each individual patient. These issues and differences between initial, controlled clinical trials and real-world care will always be present when translating any new therapy or testing methodology into routine clinical use. Nonetheless this naturalistic care will always be present when translating any new therapy or testing methodology into routine clinical use. Nonetheless this naturalistic care will always be present when translating any new therapy or testing methodology into routine clinical use.

Conclusion

The use of the STA*R test in routine clinical practice can enable significant improvement in clinically important outcomes for psychiatric patients. Hopefully, as the use of personalized medicine increases, more evidence from routine clinical practice will emerge that assesses outcomes for appropriately used PGx testing. As the healthcare environment continues to change in the United States, it will be more important to evaluate the impact of new technologies, including PGx testing, on clinical outcomes in order to justify their use [13,15]. In routine clinical care, if such testing results in significantly better improvement in symptom burden, as found here, the increased costs of testing may be justified. Further, if real-world outcomes are better for tested patients, this may encourage psychiatrists to incorporate use of this technology to benefit their patients and payers to provide access to and coverage for PGx tests.

Disclosures

Sandeep Vaishnavi and Elizabeth Griffin are employees of Carolina Partners, a North Carolina psychiatric practice

Qian Liu has no conflicts. Timothy Ramsey is a shareholder in SureGene, LLC and employee of Clinical Reference Laboratories. Mark Brennan is a shareholder in SureGene, LLC

References

1. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, et al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163: 1905-1917.
2. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, et al. (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66: 15-27.
3. Hall-Flavin DK, Winner JG, Allen JD, Jordan JJ, Nesheim RS, et al. (2012) Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry 2: e172.
4. Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, et al. (2013) Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics 23: 535-548.
5. Staeker J, Leucht S, Laika B, Steimer W (2014) Polymorphisms in Serotonergic Pathways Influence the Outcome of Antidepressant Therapy in Psychiatric Inpatients. Genet Test Mol Markers 18: 20-31.
6. Lohoff FW, Narasimhan S, Rikers K (2013) Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder. Pharmacogenomics J 13: 464-469.
7. Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, et al. (2008) Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 13: 570-584.
8. Need AC, Keefe RS, Ge D, Grossman I, Dickson S, et al. (2009) Pharmacogenomics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet. 17: 946-957.
9. Ramsey TL, Meltzer HY, Brock GN, Mehrotra B, Jayathilake K, et al. (2011) Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response. Pharmacogenomics 12: 471-480.
10. Liu Q, Ramsey TL, Meltzer HY, Masssey BW, Padmanabhan S, et al. (2012) Sulforhodamine A41 Haploype 1 (SULT4A1-1) Is Associated With Decreased Hospitalization Events in Antipsychotic-Treated Patients With Schizophrenia. Prim Care Companion CNS Disord 14.
11. Ramsey TL, Liu Q, Masssey BW, Brennan MD (2013) Genotype variation in the SLC2C gene impacts response to atypical antipsychotics the CATIE study. Schizophr Res 149: 21-25.
12. Liu Q, Jamba M, Patrick C 3rd, Padmanabhan S, Brennan MD (2012) Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study. Pharmacogenomics 13: 1227-1237.
13. Herbst L, Andersen SE, Verge T, Rasmussen HB, Jürgens G (2013) Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenia spectrum reduce treatment costs? Basic Clin Pharmacol Toxicol 113: 266-272.
14. Hicks JK, Swen JJ, Thom CF, Sangkuhl K, Kharasch ED, et al. (2013) Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 93: 402-408.
15. Olgiati P, Bajo E, Bigelli M, De Ronchi D, Serretti A (2012) Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry 36: 147-154.

16. Gualtieri CT (2007) An Internet-Based Symptom Questionnaire That Is Reliable, Valid, and Available to Psychiatrists, Neurologists, and Psychologists. MedGenMed 9: 3.

17. Hamer RM, Simpson PM (2009) Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry 166: 639-641.

18. Benjamin Y, Drai D, Elmer G, Kafkafi N, Golani I (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284.

19. Malhotra AK, Murphy GM Jr, Kennedy JL (2004) Pharmacogenetics of psychotropic drug response. Am J Psychiatry 161: 780-796.

20. Fournier JC, DeRubeis RJ, Hoflin SD, Dimidjian S, Amsterdam JD, et al. (2010) Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis. JAMA 303: 47-53.

21. Müller DJ, Kekin I, Kao AC, Brandi EJ (2013) Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int Rev Psychiatry 25: 554-571.

22. Brandi EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, et al. (2014) Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J 14: 176-181.

23. Kilts CD, Wade AG, Andersen HF, Schlaepfer TE (2009) Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother 10:927-36.

24. Kato M, Nonen S, Serretti A, Tetsuo S, Takekita Y, et al. (2013) 5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial. J Clin Psychopharmacol 33: 131-132.